Publicaciones en las que colabora con PEDRO PÉREZ SEGURA (13)

2024

  1. Exploring gastric cancer genetics: A turning point in common variable immunodeficiency

    Journal of Allergy and Clinical Immunology: Global, Vol. 3, Núm. 2

  2. Response to Yilmaz et al.

    Anti-Cancer Drugs

2023

  1. Clinical Behavior, Mutational Profile and T-Cell Repertoire of High-Grade Neuroendocrine Tumors of the Head and Neck

    Cancers, Vol. 15, Núm. 9

  2. Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer

    Anti-Cancer Drugs, Vol. 34, Núm. 5, pp. 695-698

  3. Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer

    Oncology Letters, Vol. 25, Núm. 1

  4. Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors

    Biomedicines, Vol. 11, Núm. 4

  5. Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy

    Biomedicines, Vol. 11, Núm. 9

2022

  1. Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients

    Frontiers in Oncology, Vol. 12

  2. Genomic crossroads between non-Hodgkin’s lymphoma and common variable immunodeficiency

    Frontiers in Immunology, Vol. 13

  3. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy

    Frontiers in Oncology, Vol. 12

2021

  1. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer

    Oncologist, Vol. 26, Núm. 6, pp. e1018-e1035

  2. Serological tests in the detection of SARS-CoV-2 antibodies

    Diagnostics, Vol. 11, Núm. 4

2019

  1. Durable intracranial and extracranial response to nivolumab with appearance of secondary resistance in a heavily pretreated patient with head and neck cancer

    Head and Neck, Vol. 41, Núm. 6, pp. E86-E92